Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Am J Med. 2010 Aug;123(8):764.e1–764.e9. doi: 10.1016/j.amjmed.2010.03.018

Figure 3.

Figure 3

Joinpoint analysis of chronic myeloid leukemia (CML) patients by age at year of death. These data show that there has been an overall improvement in survival of chronic myeloid leukemia patients in the imatinib era, but that this improvement extends less well to elderly patients.